Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-150: Carboplatin, paclitaxel, bevacizumab, and atezolizumab in TTF-1 negative nonsquamous NSCLC
jRCTs041260029Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival. Started Aug 2026; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041260029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260029.